Cantor Fitzgerald began coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research report report published on Tuesday, MarketBeat.com reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Metsera’s FY2025 earnings at ($3.38) EPS.
Several other research analysts have also weighed in on the stock. Evercore ISI began coverage on shares of Metsera in a research report on Tuesday. They set an “outperform” rating on the stock. Guggenheim started coverage on Metsera in a report on Tuesday. They issued a “buy” rating and a $56.00 price target on the stock. Finally, Bank of America assumed coverage on Metsera in a report on Tuesday. They set a “buy” rating and a $38.00 price objective for the company.
View Our Latest Analysis on Metsera
Metsera Stock Down 8.1 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Articles
- Five stocks we like better than Metsera
- The 3 Best Fintech Stocks to Buy Now
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What Are the U.K. Market Holidays? How to Invest and Trade
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Short Selling: How to Short a Stock
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
